Introduction
The nonobese diabetic (NOD) mouse, the most widely used animal model for studying type 1 diabetes (T1D), spontaneously develop autoimmunity characterized by a T-cell mediated inflammatory process, which ultimately leads to the destruction of insulin-producing b cells. [1] [2] [3] [4] Prevention of T1D could be obtained by arresting the chronic destruction of pancreatic b cells. This can be achieved by inducing specific tolerance to autoantigens while islet cell mass is still able to produce sufficient insulin for maintaining normal levels of blood glucose.
Proinsulin is normally expressed in b cells and has been identified as a possible autoantigen. [5] [6] [7] [8] It has been indicated that NOD transgenic mice expressing proinsulin II did not develop diabetes. 6 In contrast, in NOD mice, insufficient proinsulin II expression (ins2 À/À ) within both thymus and peripheral immune competent organs accelerated diabetes. 9, 10 Different defects of the immune system in NOD mice may play a role in the loss of tolerance to pancreatic autoantigens. Low levels of CD86 (B7.2) expression seem to contribute to a defective regulation of autoreactive T cells by preventing their full activation and the upregulation of CTLA-4 (CD152). 11 It has been reported that on cell surface of NOD bone marrow dendritic cells (DCs), there is deficient expression of MHC class II, CD80 (B7.1), CD86 (B7.2) and CD40. 12 Also, a developmental defect in splenic macrophages of NOD mouse was found responsible for their inability to process and/or present autoantigens in a tolerogenic fashion, while allowing them to retain the capacity to activate autoreactive T cells in the periphery. 13 These defects in costimulatory molecules might result in insufficient presenting of antigen signals contributing to deficiently activated (suboptimal) T cells unable to undergo negative selection but sufficient to mount autoimmunity. [14] [15] [16] [17] It has been indicated that in NOD mice, the islet-reactive T cells were refractory to CTLA-4 and their ability to escape peripheral regulation might be greatly increased as well. 18 Importantly, CD28 À/À ko NOD mice, in which CD28/B7s interactions are null, developed an earlier onset of diabetes, increased incidence and severity of autoimmunity. [19] [20] [21] Recently, the genetic mapping of T1D has shown that susceptibility is associated with a variation in CTLA-4 gene splicing. A reduced production of a spliced form encoding a molecule lacking the CD80/CD86 ligand-binding domain contributed to the autoimmune tissue destruction in human and NOD mice 22 ( Figures 1 and 2 ). DNA vaccination by nonviral techniques, such as the intramuscular (i.m.) injection of naked plasmid DNA, permits local or systemic delivery of immunomodulatory molecules along with the autoantigens to modulate immunoresponses. [23] [24] [25] [26] DNA vaccines have the advantage that they can be very easily formulated and also the antigen and expression sites can be chosen at will. Moreover, recombinant DNA techniques allow for sequence modifications to improve efficacy, safety and the addition of supplemental elements. Our previous studies have shown that induction of tolerance can be achieved after immunizing recipient NOD mice with plasmid DNA encoding islet antigens by i.m. injection. 26 In this study, we have constructed a new type of autoantigen-carrying DNA vector encoding membranebound Preproinsulin (mbPPI), which is not secreted when i.m. delivered into recipients. In order to compare the effect on the tolerance induction to PPI by either promoting or blocking antigen presentation, we have also constructed immuneregulatory vectors encoding mB7.1/CD40L or CTLA4/Fc for DNA vaccination study. DNA vaccination using mbPPI and mB7.1/CD40L DNA vaccines has been evaluated for the induction of tolerance to PPI in NOD mice models.
Results

Confirmation of mbPPI expression by RT-PCR and insulin ELISA
To determine if mbPPI is membrane-bound protein, COS-7 cells were transiently transfected with mbPPI expression vector for 72 h. From transfected supernatants, insulin protein was not detectable by insulin ELISA. This result showed that mbPPI was not expressed as soluble protein. However, the transcripts of mbPPI could be detected either from transiently transfected COS-7 cells (Figure 3a) or from DNA injected muscles (Figure 3b ) by RT-PCR with pair of primers that specifically amplify mbPPI gene, a 540-bp PCR product as described in Materials and methods.
Expression of mB7.1/CD40L and CTLA4/Fc constructs in vitro and in vivo COS-7 cells were transiently transfected with purified mB7.1/CD40L and CTLA4/Fc DNA vectors and cultured in either DMEM with 10% FBS or serum-free Opti-MEM. The expressions of these soluble fusion proteins from 72 h-transfected supernatants were detected by ELISA (Figure 4a and b) , in which mB7.1/CD40L and CTLA4/Fc transfected supernatants (1:40 dilution) showed much higher OD readings compared with control supernatants that confirmed these fusion proteins were expressed as soluble proteins. Western blot showed that these fusion proteins have homodimer conformation ( Figure 5 ). Mouse PPI and a transmembrane sequence from mouseCD80 cDNA were amplified by PCR separately. Two PCR products were used as templates for second round (overlapping) PCR to generate mbPPI. mbPPI was cloned into expression vector VR1255. 
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For in vivo transgenic expression, 6-8-week-old female NOD mice were i.m. injected with DNA vectors encoding mB7.1/CD40L or CTLA4/Fc. Mice were sacrificed 15 days after DNA vector injection and sera were tested for protein expression. ELISA results using specific antibodies shown that sera (1:3 dilution) from mB7.1/CD40L or CTLA4/Fc injected mice had much higher OD reading compared with sera from mice injected with blank vector that confirmed detectable levels of proteins from transfected genes in circulation ( Figure 6 ).
Protection of autoimmune diabetes
To test whether PPI could protect from autoimmune diabetes in NOD mice, we had delivered this expression DNA vector into young female NOD mice by i.m. injection combined with electroporation. We found that mPPI alone only slightly reduced diabetes incidence, but when mPPI vaccine was codelivered with a DNA vector encoding a fusion protein mB7.1/CD40L, it prevented insulitis and autoimmune diabetes effectively ( Figure  7a ). Also, we found that CTLA4/Fc could antagonize mPPI protective effects on insulitis and diabetes when codelivered with mbPPI into young NOD mice ( Figure  7b ). Histology has shown that islets from protected mice mostly remained insulitis-free compared with islets from diabetic mice that showed evident insulitis ( Figure 8 ).
Discussion
Administration of insulin, or its B:9-23 peptide, to NOD mice through different routes has been proven to protect mice from diabetes. [27] [28] [29] [30] [31] Also, a peptide spanning the B-C junction of proinsulin I (p24-33 epitope) has shown to be an early autoantigen for T1D pathogenesis and was protective against TID when NOD mice were immunized with this peptide. 32, 33 T cells responses to PPI epitopes have been observed in the NOD mice model. 34 DNA immunization against insulin or its peptide constructs has produced controversial results. NOD mice immunized with a plasmid encoding the B chain of insulin by i.m. injection had a lower disease incidence and delayed onset of disease. 35, 36 However, when Induction of tolerance to autoantigen preproinsulin Y Chang et al recombinant DNA encoding murine insulin A and B chains fused to IgG-Fc (insulin B chain/Fc) was i.m. injected into young NOD mice, early onset and accelerated progression of diabetes were observed. 37 Some study has also shown that in female NOD mice, diabetes development was enhanced after PPI DNA treatment. 38 Thus, it is critically important to choose the correct target antigens and antigen form that can deliver b-cell antigens in tolerogenic fashion.
In order to regulate immune response to PPI by presenting tolerogenic signals to T cells, we constructed a new DNA vaccine vector encoding a nonsecreted mbPPI. Hyperglycemia seems to be the basis of many complications in T1D patients. However, there always is the risk of causing hypoglycemia regardless to routes of administration particularly when insulin is used as a means for the intervention in T1D. mbPPI should reduce the risk of low blood glucose generally associated with native vaccines like insulin or its encoding DNA vaccines. Also, we constructed DNA vectors encoding soluble CD40L/ IgG1 or mB7.1/CD40L fusion proteins. CD40L engagement with CD40 on APCs upregulates CD80 (B7.1), CD86 (B7.2) and other costimulatory molecules that drive T cell further activation. Also, CD40L could play an important tolerogenic role and was needed as tolerogenic signal for B cells to increase expression of Fas (CD95) that triggered the death and deletion of self-reactive B and T cells through Fas-FasL interaction. [39] [40] [41] [42] Furthermore, studies have shown that the expression of CD40L was required for efficient thymic-negative selection, in which CD5 and CD28 were involved. 43 Our results had demonstrated that splenic cells treated in vitro with soluble CD40L or mB7.1/CD40L protein could increase the CD86 + cell population. Similarly, cell population detected with mAb to B220, a marker for B lymphocytes, were increased (unpublished data). We hypothesized that these CD86 + APCs, perhaps in a large percentage activated B cells, played their role in presenting antigen signals to T cells. Also the soluble CD86 molecule produced by intramuscularly delivered DNA vector could participate in T-cell-negative regulation via CTLA4/CD86 interaction.
In this study, we found that mbPPI could not be an effective tolerogenic antigen per se. This was consistent with our previous finding that DNA vector encoding a soluble PPI could not protect against autoimmune diabetes.
26 A combination of mbPPI and soluble CD40L also could not protect against autoimmune diabetes (data not shown). We reasoned that it was possible that although detectable after i.m. injection, protein level of CD40L in blood circulation was not sufficient to induce enough CD86 + cells, so that activated T cells could not be negatively regulated through CTLA4/B7s. Our results Induction of tolerance to autoantigen preproinsulin Y Chang et al also showed that mB7.1/CD40L itself did not offer any protection against autoimmune diabetes. However, when combined with mbPPI, mB7.1/CD40L were able to prevent T1D in NOD mice. Thus, mutant B7.1 portion of mB7.1/CD40L was definitely necessary and played a crucial role in this induction of tolerance to antigen PPI. We hypothesized that due to its binding specificity, mB7.1/CD40L can directly bind to CTLA4 on circulated fresh antigen-activated autoreactive T cells and resting autoreactive T cells while released right after i.m. administration and therefore induce negative regulation to these reactive T cells, which could be both suboptimal and already activated T cells. Also, this protein is a homodimer that might have higher affinity to bind CTLA4 than its wild-type form. We assumed that both soluble mutant CD80 (mB7.1/CD40L) and CD86 on CD40L-expanded cells participated in negative regulation. APCs of mice immunized with mbPPI and mB7.1/ CD40L could present effectively PPI antigen signal to T cells. As a result, these antigen-activated T cells could undergo tolerance through negative regulation. Moreover, It has been indicated that CD40L could function in a non-cell-antonomous manner during negative selection, which means that CD40-CD40L-dependent negative selection does not require CD40L to be expressed on those thymocytes that are undergoing negative selection. 42 We hypothesized that central selection may also play a role for tolerance induction in this model. However, this assumption needs further experimental evidence. Consistently with others, our results also showed that blockage of costimulatory CD28/B7s and/ or CTLA4/B7s by delivering soluble CTLA4/Fc exacerbated diabetes. CD80 and CD86 are required to negatively regulate autoreactive T cells. This supported that the deficiency in autoantigen presentation and the defective activation of T cells contributed to autoimmunity and diabetes in NOD mice.
We have observed that syngeneic splenic cells treated with PPI and mB7.1/CD40L could delay and reduce diabetes incidence when adoptively transferred into young NOD mice. Our in vitro results have shown that the prediabetic NOD spleen cells treated with PPI and mB7.1/CD40L protein could decrease INFg production (data submitted for publication). It has been demonstrated that LPS-activated B cells could downregulate pathogenic T-cell responses by inducing apoptosis of both diabetogenic T cells and activated B cells. Those activated B cells contributed to the maintenance of peripheral self-tolerance and prevented autoimmune diabetes in NOD mice. 44 A recent study has demonstrated that syngeneic transplantation of hematopoietic stem cells (HSC), most likely by generating transgenic APCs, encoding proinsulin totally prevented the development of spontaneous autoimmune diabetes in NOD. 45 In summary, codelivery of a membrane bound PPI DNA vaccine with an mB7.1/CD40 encoding vector could prevent autoimmunity and T1D in NOD mouse. In contrast, when codelivered with mbPPI, CTLA4/Fc exacerbated diabetes. These studies supported working hypothesis that deficient T-cell activation might be responsible for failure of negative selection or tolerance induction to autoantigens, leading to T1D. More importantly, our studies suggest that this new type of vaccine can be well suited for future clinical applications.
Materials and methods
Animals
Female NOD mice of 4 weeks old were purchased from Jackson Laboratory (Bar Harbor, ME, USA) and housed in specific pathogen-free facilities at Rangos Medical Research Center in Children's Hospital of Pittsburgh. All animal protocols were approved by Animal Research and Care Committees (ARCC) of Children's Hospital of Pittsburgh. Blood glucose of NOD mice was monitored starting at 10-12 weeks of age.
Construction of autoantigen DNA vaccine and immunoregulatory molecular vectors
Murine PPI was cloned and was fused to a transmembrane sequence of CD80 (B7.1) to generate mbPPI by overlapping PCR as previously described. 26, 46, 47 This mutant B7.1 (a gift from Dr Yang Liu, Ohio University) binds to CTLA4 but not to CD28. 48, 49 The extracellular sequence of CD40L (mouse CD40L cDNA from ATCC, Manassas, VA, USA) was amplified by PCD (5 0 primer C: AAGAGCCTCTCCCACTCTCCTGGTAG ATTGGATAAGGTCGAAGAGGAA and 3 0 primer D: TAGTAGGAATTCACTGTTCAGAGTTTGAGTAAGCCA). Two fragments were used as templates for second round PCR using primer A and D as described above to generate fusion gene mB7.1-Fc-CD40L (mB7.1/CD40L) ( Figure 2 ). CTLA4/Fc was generated by overlapping PCR to fuse CTLA4 gene (from Dr Lieping Chen, John Hopkins University) to murine Fc sequence of IgG1. Both fusion genes were cloned into VR1255 plasmid vector (Vical Inc, San Diego, CA, USA).
Detection of in vitro expression of mbPPI and immunoregulatory molecules
Plasmid DNA vectors were amplified and purified by QIAGEN Endofree plasmid Giga kit (QIAGEN Inc., Valencia, CA, USA), according to manufacture's instruction. Purified DNA was dissolved in 0.85% saline.
To confirm mbPPI expression, COS-7 cells were transfected with plasmid DNA by Fugen-6 (Roche diagnostics Corp., Indianapolis, IN, USA). Insulin protein was tested from supernatants 3 days after transfection by using mouse insulin ELISA kit (ALPCO Diagnostics, Windham, NH, USA). mbPPI transcription Induction of tolerance to autoantigen preproinsulin Y Chang et al from transfected cells was analysed by RT-PCR. Total RNA was isolated from transfected cells by trizol procedure and cDNA were synthesized and amplified by PCR by using one-step RT-PCR system (Invitrogen, Carlsbad, CA, USA) with a unique primer set (5 0 primer ATGGCCCTGTTGGTGCACTTC and 3 0 primer TTTGAT GATGACAACGATGAC) that specifically amplified a 540-bp amplifier from mbPPI, since its 5 0 primer matches PPI and its 3 0 primer matches transmembrane sequence.
To confirm secretion of soluble immunoregulatory molecules, COS-7 cells were transiently transfected with plasmid DNA vectors encoding mB7.1/CD40L and CTLA4/Fc and cultured either in DMEM with 10% FBS or serum-free Opti-MEM. The 72 h-transfected supernatants were analysed for protein secretions by ELISA. An anti-mouse CD40L as capture Ab and an anti-mouse CD80 as detection Ab (BD Pharmingen, San Diego, CA, USA) were used for ELISA to detect mB7.1/CD40L fusion protein. An anti-mouse CTLA4 as capture Ab and an anti-mouse IgG1 as detection Ab (BD Pharmingen, San Diego, CA, USA) were used for ELISA to detect CTLA4/Fc fusion protein. These fusion proteins were further analysed by Western blot. Fusion proteins from serum-free medium were separated on 12% nondenatured PAGE gel and transferred into PVDF membrane. The proteins were probed with anti-mouse IgG antibody (BD Pharmingen, San Diego, CA, USA).
Confirmation of in vivo transgenic expression
mbPPI, mB7.1/CD40L and CTLA4/Fc vectors were i.m. administrated into tibialis anterior muscles with 50 mg/muscle of plasmid. After DNA injection, electroporation was immediately applied to DNA injected muscles by caliper-type electrodes of ECM830 (Genetronics Inc., San Diego, CA, USA) as we have previously described. 26, 50 For mbPPI in vivo expression, mbPPI transcripts were detected from DNA injected muscles by RT-PCR. Briefly, mice were killed and DNA vector-injected TA muscles were excised and homogenized. Total mRNA was isolated by trizol procedure and transcripts were analysed by RT-PCR following the same protocol as described for mbPPI-transfected COS-7 cells.
In vivo expressions of immunoregulatory molecule fusion proteins mB7.1/CD40L and CTLA4/Fc were confirmed by protein levels in the sera of mice receiving DNA injections by ELISA.
DNA vaccination
For DNA vaccination, 4-week-old female NOD mice received i.m. DNA injection (100 mg/muscle) for a total 500 mg DNA in five injections. For these five DNA injections, tibialis anterior muscles of both sides were alternatively injected with plasmid DNA in 3 weeks apart. When two plasmids were codelivered in the same site, they were mixed in equal amounts (50 mg:50 mg) prior to i.m. injections. The same total amount of blank was always injected as for the experimental groups.
Diagnosis of diabetes and histology of insulitis
Blood glucose levels were monitored once weekly with a Precision QID Meter (MediSense, Incorporated, Bedford, MA, USA) when mice were at 12 weeks of age. Diabetes was defined by two consecutive nonfasting blood glucose levels 4300 mg/dl. For analysis of insulitis, mice were killed and pancreas was fixed in 10% buffered formalin and histological slides were prepared and stained with hematoxylin & eosin. Insulitis was determined as previously described. 26, 46, 47 
Statistical analysis
The Chi-square (w 2 ) statistical analysis was performed. Statistical significance is defined as Po0.05.
